Key facts
- It has raised $14.1M; the latest was Later Stage VC ($14.1M) in Dec 2025.
- Notable investors include Frees Fund, Lapam Capital, Zhuhai Gree Financial Investment, GF Qianhe, Zhuhai Technology Venture Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Rezubio
- ·The full record, as it builds
Funding rounds
No funding rounds for Rezubio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rezubio
Developer of tissue-selective new drugs designed to deliver more efficient and safe drugs to patients. The company's drugs are used for the treatment of autoimmune diseases, tumors, and metabolic diseases and avoid the systemic toxic side effects caused by the drug reaching the systemic circulation, it drug molecule acts on G-protein-coupled receptors on the basal lateral surface of the gut epithelium cells, yet with extremely low absorption into the blood circulation, enabling patients to that suffer from metabolic diseases, inflammatory diseases and other degenerative diseases to be treated safely and glucose reduction, body weight reduction, and low systemic drug exposure across the preclinical species.
- Sector
- Healthcare
- HQ
- Zhuhai, China
- Founded
- 2019
- Employees
- 5
- Website
- rezubio.com/
- Ownership
- Privately Held (backing)
Rezubio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rezubio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rezubio in its N-PORT filings yet. We sweep new filings monthly.